When a company such as Harvard Bioscience splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the HBIO split history from start to finish, an original position size of 1000 shares would have turned into 1319 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Harvard Bioscience shares, starting with a $10,000 purchase of HBIO, presented on a split-history-adjusted basis factoring in the complete HBIO split history.